Share: Facebook Twitter LinkedIn
Activity Provided By:

i3 Health

Clinical Updates and Expert Guidance in Prostate Cancer

Access Activity

Overview / Abstract:

STATEMENT OF NEED

Prostate cancer is the most common tumor type affecting men in the United States, with an estimated 174,650 new cases reported each year. Typically, androgen deprivation therapy is administered for progressive disease. However, castration resistance or unresponsiveness to androgen deprivation therapy or to antiandrogens frequently develops over time. The transition from castration-sensitive to castration-resistant disease has yet to be understood and represents a significant unmet need. Nonmetastatic castration-resistant prostate cancer (CRPC) is a highly heterogeneous disease process with a dearth of effective treatment options. Metastatic CRPC is the primary cause of prostate-related mortality, accounting for an estimated 31,620 deaths annually. Median overall survival remains less than 2 years.

TARGET AUDIENCE

Medical oncologists, radiation oncologists, urologists, and other health care professionals involved in the treatment of patients with prostate cancer.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

1.) Evaluate recent efficacy and safety data on novel therapeutic strategies for patients with castration-sensitive/resistant nonmetastatic prostate cancer
2.) Evaluate emerging efficacy and safety data on novel therapeutic strategies for patients with castration-sensitive/resistant metastatic prostate cancer
3.) Assess recent study findings on novel combination and sequential treatment strategies for prostate cancer and their implications for current practice

Expiration

Jun 04, 2020

Discipline(s)

Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME

Format

Live / Seminar, Online, Webinar / Webcast / Video

Credits / Hours

1.0 CME

Accreditation

ACCME

Is This Activity Certified for "Live" Credit?

YES

Presenters / Authors / Faculty

Judd W. Moul, MD
Professor of Urologic Surgery
Duke University School of Medicine

Sponsors / Supporters / Grant Providers

This activity is supported by an independent educational grant from Sanofi.

Keywords / Search Terms

i3 Health i3 Health i3 Health, prostate cancer, online CNE, free CNE, free CE CME, free CE CME, free CE CME, NCPD, free NCPD, online NCPD, online NCPD CME, Live CE CME Seminar CE CME Free CE CME Live CE CME Seminar CE CME

LIVE Activity Location Details

Date(s)
05-29-2020

i3 Health
NJ  
United States of America

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map